 NEW YORK, Nov. 12, 2020 GLOBE NEWSWIRE -- Ovid Therapeutics Inc. NASDAQ: OVID, a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update. 